Can-Fite Biopharma Ltd ADR (CANF)

$0.65 0.00 (-0.05%)
Market Cap 2.31M
Revenue (ttm) 670,000.00
Net Income (ttm) -7.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,176.12%
Debt to Equity Ratio 0.00
Volume 99,200
Avg Vol 205,136
Day's Range N/A - N/A
Shares Out 3.54M
Stochastic %K 52%
Beta 1.06
Analysts Strong Sell
Price Target $7.75

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 924 1114
Fax: 972 3 924 9378
Address:
26 Ben Gurion Street, Ramat Gan, Israel
whatascam
whatascam Sep. 5 at 5:40 PM
$CANF Somebody should tell them…
1 · Reply
Tryingtoretire01
Tryingtoretire01 Sep. 5 at 1:24 PM
$CANF adding at .65ish....it will go in a few.
0 · Reply
JarvisFlow
JarvisFlow Sep. 2 at 11:30 AM
D. Boral Capital updates rating for Can Fite Biofarma ( $CANF ) to Buy, target set at 11.
0 · Reply
NowaYT
NowaYT Aug. 12 at 10:43 PM
$CANF
0 · Reply
mOTCallouts
mOTCallouts Aug. 5 at 5:36 PM
$CANF 5 days in the green 🚀
0 · Reply
mOTCallouts
mOTCallouts Aug. 5 at 8:43 AM
$CANF give me.7 🚀
0 · Reply
BBop
BBop Aug. 4 at 9:01 PM
$CANF 2 phase 3 trials and we’re under $1?
0 · Reply
mOTCallouts
mOTCallouts Aug. 4 at 8:03 PM
$CANF slow and steady uptrend going to give it 2 more days for some action. If the volume stays low I'm jumping out
0 · Reply
kubota2323
kubota2323 Aug. 3 at 6:54 PM
$CANF nothing but a pump and dump. Pure trash
0 · Reply
mOTCallouts
mOTCallouts Aug. 1 at 7:50 PM
$CANF jumped in, oversold. let's see where she goes next week.
1 · Reply
Latest News on CANF
Can-Fite Reports H1 2025 Financial Results and Clinical Update

Aug 28, 2025, 8:47 AM EDT - 10 days ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Jul 30, 2025, 7:04 AM EDT - 5 weeks ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Can-Fite Announces Up To $15.0 Million Public Offering

Jul 28, 2025, 12:24 PM EDT - 5 weeks ago

Can-Fite Announces Up To $15.0 Million Public Offering

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Jul 28, 2025, 7:00 AM EDT - 5 weeks ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Apr 17, 2025, 8:55 AM EDT - 5 months ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Apr 14, 2025, 2:28 PM EDT - 5 months ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Mar 20, 2025, 9:45 AM EDT - 6 months ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Mar 19, 2025, 9:00 AM EDT - 6 months ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Mar 3, 2025, 6:00 AM EST - 6 months ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Feb 10, 2025, 7:10 AM EST - 7 months ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Feb 5, 2025, 7:00 AM EST - 7 months ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Dec 30, 2024, 7:00 AM EST - 8 months ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 22, 2024, 9:00 AM EST - 10 months ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SXTP

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Nov 11, 2024, 7:00 AM EST - 10 months ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Nov 4, 2024, 7:08 AM EST - 10 months ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Oct 18, 2024, 9:06 AM EDT - 11 months ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Oct 9, 2024, 7:00 AM EDT - 11 months ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Aug 29, 2024, 8:15 AM EDT - 1 year ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 9, 2024, 9:00 AM EDT - 1 year ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Aug 8, 2024, 7:01 PM EDT - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Can-Fite Provides Namodenoson Patent Update

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Provides Namodenoson Patent Update

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 17, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 29, 2024, 7:00 AM EDT - 1 year ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 27, 2024, 7:00 AM EDT - 1 year ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 23, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 13, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

May 10, 2024, 9:00 AM EDT - 1 year ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 9, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

May 6, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 15, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Can-Fite Reports 2023 Financial Results and Clinical Update

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Reports 2023 Financial Results and Clinical Update

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Feb 28, 2024, 7:00 AM EST - 1 year ago

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Jan 30, 2024, 7:00 AM EST - 1 year ago

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

Jan 29, 2024, 7:00 AM EST - 1 year ago

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

The Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Dec 20, 2023, 7:00 AM EST - 1 year ago

The Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Can-Fite's Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Dec 4, 2023, 7:00 AM EST - 1 year ago

Can-Fite's Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Nov 30, 2023, 7:00 AM EST - 1 year ago

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

Nov 21, 2023, 1:53 PM EST - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

Nov 21, 2023, 7:00 AM EST - 1 year ago

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

whatascam
whatascam Sep. 5 at 5:40 PM
$CANF Somebody should tell them…
1 · Reply
Tryingtoretire01
Tryingtoretire01 Sep. 5 at 1:24 PM
$CANF adding at .65ish....it will go in a few.
0 · Reply
JarvisFlow
JarvisFlow Sep. 2 at 11:30 AM
D. Boral Capital updates rating for Can Fite Biofarma ( $CANF ) to Buy, target set at 11.
0 · Reply
NowaYT
NowaYT Aug. 12 at 10:43 PM
$CANF
0 · Reply
mOTCallouts
mOTCallouts Aug. 5 at 5:36 PM
$CANF 5 days in the green 🚀
0 · Reply
mOTCallouts
mOTCallouts Aug. 5 at 8:43 AM
$CANF give me.7 🚀
0 · Reply
BBop
BBop Aug. 4 at 9:01 PM
$CANF 2 phase 3 trials and we’re under $1?
0 · Reply
mOTCallouts
mOTCallouts Aug. 4 at 8:03 PM
$CANF slow and steady uptrend going to give it 2 more days for some action. If the volume stays low I'm jumping out
0 · Reply
kubota2323
kubota2323 Aug. 3 at 6:54 PM
$CANF nothing but a pump and dump. Pure trash
0 · Reply
mOTCallouts
mOTCallouts Aug. 1 at 7:50 PM
$CANF jumped in, oversold. let's see where she goes next week.
1 · Reply
Rasto2020
Rasto2020 Jul. 31 at 11:48 PM
$CANF also on 1 hour chart it’s inverted head and shoulder
0 · Reply
Rasto2020
Rasto2020 Jul. 31 at 11:47 PM
$CANF very oversold., I know they jist had an offerings , but I’ll be watching
0 · Reply
type12
type12 Jul. 31 at 2:27 AM
$CANF I can’t help but feel that I’m going to be fucked no matter what😳
0 · Reply
BioRich
BioRich Jul. 30 at 4:16 PM
$CANF Surprised I hadn't seen this before. CANF has 7 partnerships in place? And they expect these partnerships to be worth ~$685M? That's huge! Here's the breakdown: $XBI $CADL $PFE $LLY
0 · Reply
mmerryweather
mmerryweather Jul. 30 at 2:05 PM
$CANF The buyer of 8.3 million shares at $.60 per share also owns 16.6 million warrants to exercise at $.60 per share. The buyer will continue to exercise the warrants and sell the stock into the market at $.70 per share. This will reduce the buyer's basis on the existing 8.3 million shares. The sale of 16.6 million shares will last for MANY MONTHS TO COME. Nothing CON-file can announce will move the stock up. The seller will be there forever. Have a nice day!
0 · Reply
mmerryweather
mmerryweather Jul. 30 at 11:22 AM
$CANF On 7-28-2025 at 7:58 AM I posted that Con-fite would release an additional "news story" within the next 24 to 48 hours. Well they DID release a second story that means ABSOLUTELY NOTHING. This is what CON artists do. Again - I am a buyer for a short term trade at $.58 per share. Massive money can be made on the other side of the CON. Have a nice day and enjoy your tax loss for 2025. What a killing all of you have taken.
0 · Reply
trader2360
trader2360 Jul. 30 at 11:12 AM
$CANF grab it
0 · Reply
TA_Kongen
TA_Kongen Jul. 30 at 11:09 AM
$CANF Already dropped myb.
0 · Reply
Danypoopoo
Danypoopoo Jul. 30 at 11:07 AM
$CANF https://ir.canfite.com/news-events/press-releases/detail/1091/pancreatic-cancer-phase-2a-study-with-can-fites
0 · Reply
TA_Kongen
TA_Kongen Jul. 30 at 11:07 AM
$CANF Effect on s-1. Now a matter of time before offering news drop. Likely today or tomorrow.
0 · Reply
hassle
hassle Jul. 29 at 8:01 PM
$CANF It is amazing this company can produce wonder drug(s) that can cure anything and everything across totally different unrelated ailments, cancer, obesity, erectile dysfunction, liver diseases, immune system disease, and more coming for sure, basically you name it. Too bad, If only they could claim they can cure my long suffering stupidity, I'll sell my kidney to buy this.
0 · Reply
whatascam
whatascam Jul. 29 at 6:29 PM
$CANF Only joking. It's trash.
1 · Reply